These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31759363)

  • 1. Predictive Value of Neutrophil to Lymphocyte Ratio in the Diagnosis of Significant Prostate Cancer at Initial Biopsy: A Comparison with Free Percent Prostate Specific Antigen, Prostate Specific Antigen Density and Primary Circulating Prostate Cells.
    Murray NP; Fuentealba C; Reyes E; Lopez MA; Salazar A; Minzer S; Munoz L; Orrego S; Guzman E; Arzeno L
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3385-3389. PubMed ID: 31759363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer.
    Murray NP; Reyes E; Fuentealba C; Orellana N; Morales F; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(13):5365-70. PubMed ID: 26225679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in Chile.
    Murray NP; Reyes E; Fuentealba C; Jacob O; Orellana N
    Asian Pac J Cancer Prev; 2014; 15(21):9335-9. PubMed ID: 25422221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.
    Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Dueñas R
    Arch Esp Urol; 2013 May; 66(4):335-41. PubMed ID: 23676536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy.].
    Murray NP; Fuentealba C; Reyes E; Jacob O
    Arch Esp Urol; 2017 Jun; 70(5):503-512. PubMed ID: 28613202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head to Head Comparison of the Chun Nomogram, Percentage Free PSA and Primary Circulating Prostate Cells to Predict the Presence of Prostate Cancer at Repeat Biopsy.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2016; 17(6):2941-6. PubMed ID: 27356715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(2):601-6. PubMed ID: 25684494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Using Sequential Primary Circulating Prostate Cell Detection for Initial Prostate Biopsy in Men Suspected of Prostate Cancer.
    Murray NP; Reyes E; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2016; 17(7):3385-90. PubMed ID: 27509980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3375-3381. PubMed ID: 30583343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-head comparison of the Montreal nomogram with the detection of primary malignant circulating prostate cells to predict prostate cancer at initial biopsy in Chilean men with suspicion of prostate cancer.
    Murray NP; Reyes E; Fuentealba C; Orellana N; Jacob O; Badilla S
    Urol Oncol; 2015 May; 33(5):203.e19-25. PubMed ID: 25746939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative performance analysis of total PSA, percentage free PSA, PSA velocity, and PSA density versus the detection of primary circulating prostate cells in predicting initial prostate biopsy findings in Chilean men.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Dueñas R
    Biomed Res Int; 2014; 2014():676572. PubMed ID: 25101294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
    Murray NP; Reyes E; Tapia P; Orellana N; Dueñas R; Fuentealba C; Badinez L
    Arch Esp Urol; 2011 Dec; 64(10):961-71. PubMed ID: 22228894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet-to-lymphocyte ratio and systemic immune-inflammation index versus circulating prostate cells to predict significant prostate cancer at first biopsy.
    Murray NP; Fuentealba C; Salazar A; Reyes E
    Turk J Urol; 2020 Mar; 46(2):115-122. PubMed ID: 32053099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B; Alkibay T; Tuncel A; Bozkirli I
    Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of 3 on-line nomograms with the detection of primary circulating prostate cells to predict prostate cancer at initial biopsy.
    Murray NP; Fuentealba C; Reyes E; Jacob O
    Actas Urol Esp; 2017 May; 41(4):234-241. PubMed ID: 28108045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.
    Caglayan V; Onen E; Avci S; Sambel M; Kilic M; Oner S; Aydos MM; Yıldız HE
    Arch Ital Urol Androl; 2019 Jan; 90(4):270-275. PubMed ID: 30655640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy.
    Kawahara T; Fukui S; Sakamaki K; Ito Y; Ito H; Kobayashi N; Izumi K; Yokomizo Y; Miyoshi Y; Makiyama K; Nakaigawa N; Yamanaka T; Yao M; Miyamoto H; Uemura H
    Oncotarget; 2015 Oct; 6(31):32169-76. PubMed ID: 26359354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.